Raytheon awarded $71 million in Navy contracts for missile systems
David Badawi, the Chief Technology Officer of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold 5,980 shares of the company’s common stock. The transaction, which took place on April 1, 2025, was executed at a price of $2.303 per share, amounting to a total value of approximately $13,771. The sale comes as the stock trades near its 52-week low of $2.04, having declined over 60% in the past year. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value estimates.
The sale was conducted to cover Badawi’s tax liability associated with the vesting of restricted stock units, as noted in the filing. Following this transaction, Badawi retains direct ownership of 1,836,704 shares of Sight Sciences’ common stock. While the company maintains strong liquidity with a current ratio of 9.04 and more cash than debt on its balance sheet, InvestingPro data reveals 10+ additional key insights about the company’s financial health and market position, available exclusively to subscribers.
In other recent news, Sight Sciences Inc. reported its fourth-quarter 2024 earnings, revealing a slight miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.23, which was marginally below the anticipated -$0.22, and revenue of $19.1 million, falling short of the expected $20.26 million. Revenue for the quarter marked a 2% year-over-year increase, driven by a 9% growth in surgical glaucoma revenue, although the dry eye segment saw a significant decline. Despite the earnings miss, Sight Sciences maintains a strong gross margin, which improved to 87% from 85% the previous year.
Stifel analysts recently adjusted their price target for Sight Sciences to $4.00 from $5.00, while maintaining a Buy rating on the company’s shares. The revision followed the company’s revenue report, which did not meet expectations due to challenges in the Surgical Glaucoma segment, exacerbated by changes in Medicare Local Coverage Determinations. Analysts at Stifel believe the company’s guidance is conservative and remain optimistic about potential reimbursement for the TearCare product in 2025. They also highlight Sight Sciences’ strong balance sheet as a supportive factor for future operations.
Sight Sciences provided guidance for 2025, projecting revenue between $70 million and $75 million. The company anticipates initial reimbursement decisions for its TearCare product, which could positively impact future revenue streams. However, the company expects a decline in first-quarter revenue, potentially affecting short-term investor sentiment. Despite these challenges, Sight Sciences’ leadership expressed confidence in achieving cash flow breakeven and emphasized strategic growth in its glaucoma and dry eye markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.